Molecular Partners AG Announces Management Appointments
June 21, 2018 at 02:00 am EDT
Molecular Partners AG announced the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer. Pamela Trail served most recently as Vice President of Oncology Strategy and Program Direction at Regeneron Pharmaceuticals. With her addition the company significantly strengthens its leading research capabilities applying the DARPin® platform to oncology drug development. The company has also announced that Michael T. Stumpp, Ph.D., a co-founder of Molecular Partners and so far Chief Scientific Officer of the company, has been appointed to the role of Chief Operating Officer. Michael T. Stumpp was part of the team working on designed repeat proteins as next generation protein drugs at University of Zurich that also invented the DARPin® technology. Pamela Trail has over 30 years of experience in directing cancer drug discovery efforts at leading pharmaceutical companies worldwide. She has previously held the roles of Vice President of Oncology Research at MedImmune, Chief Scientific Officer at Seattle Genetics, Vice President of Protein Therapeutics Research at Bayer Healthcare, and Director of Oncology Cell and Tumor Biology at Bristol-Myers Squibb Pharmaceutical Research Institute. In her new role, Pamela Trail will work alongside a growing number of leading oncology and drug development and experts at Molecular Partners, including Andreas Harstrick, M.D., Chief Medical Officer, and Bill Burns, Chairman, former CEO of Roche Pharmaceuticals.